Sherwin Stephen A's Form 4 filing
Neurocrine Biosciences Inc (NBIX) · filed Jan 26, 2022
- Accession no.
- 0001209191-22-005109
- Filed
- Jan 26, 2022
- Trade date
- Jan 24, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.12M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sherwin Stephen ACIK 0001079462 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 24, 2022 | Common Stock | MOption exerciseAcquired | +15,000 | $6.66 | +$99,900 | 40,055 | Direct | |
| Jan 24, 2022 | Common Stock | SSaleDisposed | −15,000 | $74.43 | −$1,116,450 | 25,055 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 24, 2022 | Common Stock | MOption exerciseDisposed | −15,000 | $6.66 | −$99,900 | 0 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.